CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,775 enrolled
Drug / intervention
Brolucizumab ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02307682
NCT02307682Phase 3Completed
CompareCT.gov

A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration

Alcon Research·interventional·Posted Dec 4, 2014·Updated Jan 16, 2025

In Brief

A Phase 3 clinical trial evaluating Brolucizumab ophthalmic solution and Aflibercept ophthalmic solution for Neovascular Age-Related Macular Degeneration and Choroidal Neovascularization. Completed, enrolled 1,775 participants across 1 site.

Detailed Summary

The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeovascular Age-Related Macular Degeneration, Choroidal Neovascularization
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 4, 2014
Enrollment StartDec 8, 2014
Primary CompletionApr 22, 2017
Study CompletionMar 28, 2018
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.6 years ago

Interventions

Brolucizumab ophthalmic solutiondrug

Ophthalmic solution for IVT injection

Aflibercept ophthalmic solutiondrug

Ophthalmic solution for IVT injection